The "sisters" in the pharmaceutical sector, three of the top Chinese mainland women on the list.

As of June 30, 2020, 25 Chinese mainland women who entered the list of Chinese mainland's richest women this year, with a total wealth of 909.43 billion yuan, up 74.85 percent from last year's 520.130 billion yuan wealth, according to data from Pharmaceutical Network Industry DynamicsAccording to the author combing, the field of medicine has three "sisters" who ride the wind and waves on the list, respectively, Hansen Pharmaceutical's Zhong Huixuan, Qi Zhengtibetan medicine's Lei Jufang, Huaxi bio's Zhao YanAmong them, Hansen Pharmaceuticals' Zhong Huixuan with a value of 132.95 billion yuan to pped the list, this year, Hanson Pharmaceuticals' share price soared, so that its wealth accumulation "to a higher level." As of December 31, 2019, the Group achieved revenue of RMB8,683 million, up 12.4% YoY, while research and development expenditure was RMB1.121 billion, up 27.2% YoYNotably, Zhong Huixuan and his husband's daughter Sun Yuan participated in the day-to-day management of Hansen Pharmaceuticals and served as the company's executive directorThe Haussen Pharmaceuticals, led by MrZhong, also holds an important market share in the pharmaceutical sectorIn June 2019, Howson Pharmaceuticals was officially listed on the Hong Kong Stock Exchange under the name of "Hanson Pharmaceuticals"On the day of the listing, with a market capitalisation of HK$100 billion, Hong Kong stocks rose against the trend of the "breakthrough tide"In addition, Zhong Huixuan and her husband Sun Huihui are regulars on the list of the major rich, and are very high in the rankingsIn June 2020, Mrand MrsSun and MrsZhong huihui jointly held a fortune of RMB115 billion in Hurun's list of the world's top 100 entrepreneursLei Jufang is both an entrepreneur and a scientistThe wind-breaking "sister" in the 1980s from the Chinese Academy of Sciences, to paste as the main products, to create a well-known Tibetan medicine manufacturers - Qi Zheng Tibetan medicineIn 2009, Qizheng Tibetan medicine was listed on the Shenzhen Stock ExchangeQi zheng pain cream as the representative of the range of external painkillers has been selling for many years, in China's external painkillermarket sales ranking in the forefront For the whole of 2019, Qizheng Tibetan medicine achieved revenue of 1.05 billion yuan, up 13.76 percent year-on-year, accounting for 74.84 percent of operating income At present, the company has a market value of 10 billion Zhao Yan of Huaxi Bio is the founder of the kingdom of boheric acid Relying on the two core technical platforms of microbial fermentation and cross-linking, Huaxi Bio has formed the three main businessofs of hyaluronic acid raw materials, medical end products and functional skin care products, covering the complete industrial chain of hyaluronic acid raw materials and related end products Data show that in 2018 China accounted for 50% of the world's pharmaceutical-grade uric acid raw materials sales, about 10 tons, while Huaxi Bio's pharmaceutical-grade raw materials sales that year was 9.5 tons, it can be said that a large part of the stock comes from Huaxi Bio In 2019, The year of The Listing of Huaxi Bio also achieved good results, achieving operating income of RMB1.886 billion, up 49.28% YoY; 8.6 billion yuan, up 38.16 percent year-on-year Since this year, pharmaceutical stocks all the way bullish, can be described as unlimited scenery, but at the same time the differentiation is also more serious In the special period of the big test, Chinese mainland women entrepreneurs are challenging, but there are still these fearless hardships all the way through, in the pharmaceutical industry to break the waves of the "sisters." In the days to come, I would like them to continue to cover the thorns and live into a different landscape At present, the industry is generally optimistic about the long-term development space of the pharmaceutical industry, think that medicine as a new need sweaning industry, while benefiting from China's huge population base and aging process, China's pharmaceutical industry has a huge market, in the long term, the market value of these excellent enterprises still have several times the growth space At the same time, in the future, you can expect more hundreds of billions of yuan, or even trillion yuan of market value of Chinese pharmaceutical enterprises